




# September 2025

Does early treatment with highly effective DMT improve prognosis for people with MS?

## WELCOME TO THE DELIVER-MS NEWSLETTER

We would like to thank all the sites for their efforts on both DELIVER-MS and DELIVER-MS Long Term Extension (LTE). For DELIVER-LTE there are 17 sites that have enrolled at least one patient and 1 site pending activation. We have also started tracking patients who have already reached M48 and have not enrolled in the LTE. Please reach out if you have any questions about enrollment!



\*2 patients from Cardiff have transferred to Bristol and 1 from Nottingham to Leeds\*

## REMINDERS

- Please push EVERY visit to QA-data can't be downloaded unless a visit is in QA
- Complete M36 MRIs on the DELIVER approved scanner is a must and should be done without exception in the RCT trial participants
- MRIs in the LTE are flexible and preferred on DELIVER approved scanner if possible (will still accept MRIs if not on the DEL approved scanner)
- Let us know if a participant declines the LTE
- We are still pending IRB approval for the updated protocol/ICF that extends the study due to the PCORI funding. Once we have approval, we will be sending those out to the sites along with new subcontracts.**

## End of Recruitment Webinar

We held the DELIVER-MS End of Recruitment Webinar on July 7<sup>th</sup> where we discussed overall recruitment into the DELIVER-MS study and summaries of the baseline and cohorts. To access the recording please visit our website ([www.deliver-ms.com](http://www.deliver-ms.com)) and click on Study Videos.

## ECTRIMS 2025: September 24-26 Barcelona, Spain

The DELIVER-MS team will be hosting breakfast on September 25<sup>th</sup> at 8am CEST. If you can attend, please let us know so we can send the meeting details!

ECTRIMS presentations to note:

Sarah Planchon (presentation 9/25/2025 9:45-10:45am CEST Lecture Hall 113. Session: Free Communications 5: Environmental and social risk factors) **The role of social deprivation on clinical trial participation and treatment decision making in the United States and United Kingdom**

Daniel Ontaneda (presentation chair 9/25/2025 11:15-12:45pm CEST Lecture Hall Auditorium) **Scientific Session 5: Personalised treatment regimes in MS and related disorders**

Emma Tallantyre (e-poster): **Baseline characteristics of the Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-remitting MS (DELIVER-MS) trial cohort**

## FINAL THOUGHTS

We want to thank you all for your ongoing dedication to DELIVER-MS and now the LTE. Please reach out to our team if you have any questions!

---

### **Relevant Links**

**Our website is:**

[www.deliver-ms.com](http://www.deliver-ms.com)

**Our mailing address is:**

[planchs@ccf.org](mailto:planchs@ccf.org) (US) and [harriet.howard5@nhs.net](mailto:harriet.howard5@nhs.net) (UK)